Baudax Bio, Inc. – NASDAQ:BXRX

Financial Health
0
1
2
3
4
5
6
7
8
9

Baudax Bio stock price monthly change

-7.41%
month

Baudax Bio stock price quarterly change

-85.71%
quarter

Baudax Bio stock price yearly change

-99.11%
year

Baudax Bio key metrics

Market Cap
N/A
Enterprise value
3.05M
P/E
-0.01
EV/Sales
2.40
EV/EBITDA
-0.05
Price/Sales
0.94
Price/Book
-0.04
PEG ratio
N/A
EPS
-2.54
Revenue
N/A
EBITDA
-14.17M
Income
-7.15M
Revenue Q/Q
-100%
Revenue Y/Y
-76.02%
Profit margin
-4629.53%
Oper. margin
-2814.33%
Gross margin
-451.89%
EBIT margin
-2814.33%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Baudax Bio stock price history

Baudax Bio stock forecast

Baudax Bio financial statements

Baudax Bio, Inc. (NASDAQ:BXRX): Profit margin
Dec 2022 310K -9.24M -2983.55%
Mar 2023 -14K 11.40M -81457.14%
Jun 2023 30K -7.37M -24583.33%
Sep 2023 0 -1.93M
Baudax Bio, Inc. (NASDAQ:BXRX): Analyst Estimates
2025 5.07M -23.53M -463.67%
  • Analysts Price target

  • Financials & Ratios estimates

Baudax Bio, Inc. (NASDAQ:BXRX): Debt to assets
Dec 2022 10032000 34.27M 341.65%
Mar 2023 7065000 14.37M 203.51%
Jun 2023 21316000 31.99M 150.1%
Sep 2023 20583000 30.82M 149.74%
Baudax Bio, Inc. (NASDAQ:BXRX): Cash Flow
Dec 2022 -3.78M 40K 3.39M
Mar 2023 -4.66M 0 3.20M
Jun 2023 -3.44M 142K 917K
Sep 2023 -2.41M -21K 1.38M

Baudax Bio alternative data

Baudax Bio, Inc. (NASDAQ:BXRX): Employee count
Aug 2023 9
Sep 2023 9
Oct 2023 9
Nov 2023 9
Dec 2023 9
Jan 2024 9
Feb 2024 9
Mar 2024 9
Apr 2024 9
May 2024 9
Jun 2024 9
Jul 2024 9

Baudax Bio other data

1.49% -6.28%
of BXRX is owned by hedge funds
4.94K -18.05K
shares is hold by hedge funds

Baudax Bio, Inc. (NASDAQ:BXRX): Insider trades (number of shares)
Period Buy Sel
Dec 2022 1200 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
HENWOOD GERALDINE officer: Presiden.. Common Stock 1,200 $2.55 $3,058
Purchase
HENWOOD GERALDINE director, officer.. Common Stock 8,200 $0.59 $4,797
Purchase
CHURCHILL WINSTON J director
Common Stock 100,000 $0.63 $62,900
Purchase
CASTEN RICHARD S
Common Stock 50,000 $0.51 $25,500
Purchase
CHURCHILL WINSTON J director
Common Stock 25,000 $0.78 $19,525
Purchase
CASTEN RICHARD S
Common Stock 25,000 $0.79 $19,750
Purchase
BASKIES ARNOLD M director
Common Stock 10,000 $0.82 $8,200
Purchase
HENWOOD GERALDINE director, officer.. Common Stock 6,000 $0.83 $4,992
Purchase
CASTEN RICHARD S
Common Stock 25,000 N/A N/A
Purchase
ALTOMARI ALFRED director Common Stock 5,000 $1.06 $5,300
Patent
Application
Filling date: 7 Nov 2019 Issue date: 13 Jan 2022
Application
Filling date: 23 Oct 2019 Issue date: 16 Dec 2021
Application
Filling date: 5 Jun 2020 Issue date: 22 Apr 2021
Application
Filling date: 8 Mar 2019 Issue date: 8 Apr 2021
Grant
Filling date: 8 Mar 2019 Issue date: 5 Jan 2021
Grant
Filling date: 25 Aug 2019 Issue date: 14 Jul 2020
Grant
Filling date: 12 Sep 2017 Issue date: 16 Jun 2020
Wednesday, 18 October 2023
globenewswire.com
Monday, 2 October 2023
zacks.com
Thursday, 28 September 2023
InvestorPlace
Proactive Investors
Monday, 3 July 2023
Zacks Investment Research
Friday, 30 June 2023
InvestorPlace
Market Watch
Thursday, 8 June 2023
Zacks Investment Research
Tuesday, 6 June 2023
GlobeNewsWire
Wednesday, 3 May 2023
GlobeNewsWire
Thursday, 27 April 2023
InvestorPlace
Tuesday, 18 April 2023
PennyStocks
Thursday, 26 January 2023
MarketBeat
Tuesday, 24 January 2023
InvestorPlace
Friday, 30 December 2022
PennyStocks
Saturday, 24 December 2022
InvestorPlace
Friday, 9 December 2022
InvestorPlace
Tuesday, 8 November 2022
Zacks Investment Research
Monday, 24 October 2022
Zacks Investment Research
Thursday, 8 September 2022
GlobeNewsWire
Friday, 2 September 2022
24/7 Wall Street
Thursday, 1 September 2022
PennyStocks
Thursday, 11 August 2022
Zacks Investment Research
Wednesday, 18 May 2022
GlobeNewsWire
Saturday, 7 May 2022
Seeking Alpha
Thursday, 5 May 2022
GlobeNewsWire
Monday, 11 April 2022
Zacks Investment Research
Wednesday, 16 February 2022
Pulse2
Sunday, 23 January 2022
PennyStocks
Thursday, 20 January 2022
PennyStocks
  • When is Baudax Bio's next earnings date?

    Unfortunately, Baudax Bio's (BXRX) next earnings date is currently unknown.

  • Does Baudax Bio pay dividends?

    No, Baudax Bio does not pay dividends.

  • What is Baudax Bio's stock symbol?

    Baudax Bio, Inc. is traded on the NASDAQ under the ticker symbol "BXRX".

  • What is Baudax Bio's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Baudax Bio?

    Shares of Baudax Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Baudax Bio's key executives?

    Baudax Bio's management team includes the following people:

    • Dr. Geraldine A. Henwood Pres, Chief Executive Officer & Director(age: 73, pay: $441,060)
  • How many employees does Baudax Bio have?

    As Jul 2024, Baudax Bio employs 9 workers.

  • When Baudax Bio went public?

    Baudax Bio, Inc. is publicly traded company for more then 5 years since IPO on 14 Nov 2019.

  • What is Baudax Bio's official website?

    The official website for Baudax Bio is baudaxbio.com.

  • Where are Baudax Bio's headquarters?

    Baudax Bio is headquartered at 490 Lapp Road, Malvern, PA.

  • How can i contact Baudax Bio?

    Baudax Bio's mailing address is 490 Lapp Road, Malvern, PA and company can be reached via phone at +48 43952440.

Baudax Bio company profile:

Baudax Bio, Inc.

baudaxbio.com
Exchange:

NASDAQ

Full time employees:

9

Industry:

Biotechnology

Sector:

Healthcare

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

490 Lapp Road
Malvern, PA 19355

CIK: 0001780097
ISIN: US07160F4046
CUSIP: 07160F206